Co-Host: Kelvin Moses, MD

At the conclusion of these activities, participants will be able to:

1. Identify the active agents and their mechanism of action in the management of metastatic HSPC.

2. Describe the risks and benefits of treatment for metastatic HSPC.

CME Available: auau.auanet.org/node/26063

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma